Patent ID: 7713947
Filing Date: 2010-05-11
Classification: A61K,A61P

Abstract:
1. A method of treating multiple sclerosis comprising the oral administration of a formulation comprising cladribine, wherein the formulation is to be orally administered following the sequential steps below: (i) an induction period wherein said cladribine formulation is administered and wherein the total dose of cladribine reached at the end of the induction period is from about 1.7 mg/kg to about 3.5 mg/kg; (ii) a cladribine-free period of between about 8 and about 10 months wherein no cladribine formulation is administered; (iii) a maintenance period wherein said cladribine formulation is administered and wherein the total dose of cladribine reached at the end of the maintenance period is lower than the total dose of cladribine reached at the end of the induction period (i); and (iv) a cladribine-free period wherein no cladribine formulation is administered.